Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Compared to Bortezomib Alone in Patients With Multiple Myeloma in First Relapse.

Trial Profile

Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Compared to Bortezomib Alone in Patients With Multiple Myeloma in First Relapse.

Suspended
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2013

At a glance

  • Drugs Bortezomib; Tanespimycin
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms BMS-TIME-1; TIME-1
  • Sponsors Bristol-Myers Squibb; Kosan Biosciences
  • Most Recent Events

    • 19 Mar 2010 Planned end date changed from 1 Dec 2016 to 1 May 2017 as reported by ClinicalTrials.gov.
    • 07 Aug 2009 Planned number of patients changed from 550 to 740 as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Additional location (Netherlands) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top